Natural Product (NP) Details

General Information of the NP (ID: NP4234)
Name
Bismuth (III)
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Gastric ulcer [ICD-11: DA60] Investigative [1]
ADMET Property
Absporption
Caco-2 Permeability
 -4.571
 
MDCK Permeability
 -4.634
 
PAMPA
 +++
 
HIA
 -
 
Distribution
VDss
 -0.15
 
PPB
 8.9%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 +
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 +
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - -
 
Excretion
CLplasma
 6.116
 
T1/2
 2.736
Toxicity
DILI
 - -
 
Rat Oral Acute Toxicity
 ++
 
FDAMDD
 +
 
Respiratory
 +++
 
Human Hepatotoxicity
 +++
 
Ototoxicity
 - - -
 
Drug-induced Nephrotoxicity
 - -
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 +
 
Genotoxicity
 ++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
Herb ID
HBIN018632
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          6-mercaptopurine      Mature B-cell lymphoma     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Decrease Cell proliferation capacity
                    In-vitro Model A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
NCI-H460 CVCL_0459 Lung large cell carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The combination of Bi(III) with 6-MP endowed the newly developed amorphous [Bi(MP)3(NO3)2]NO3 with excellent anticancer activity against lung cancer cells and the solubility and bioavailability of the obtained [Bi(MP)3(NO3)2]NO3 were dramatically improved, compared with that of 6-MP.
References
Reference 1 Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori. Biometals. 2012 Feb;25(1):95-102.
Reference 2 Improvement in the Anticancer Activity of 6-Mercaptopurine via Combination with Bismuth(III). Chem Pharm Bull (Tokyo). 2016;64(11):1539-1545.
 Download Picture         KEGG Link